Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
ESMO Open
|
October 24, 2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
Aparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, et al.
Cell
|
May 7, 2026
Disrupted molecular glue complex drives RAS inhibitor resistance
Ben Sang, Ling Feng Ye, Zheng Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Aparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer
Daniel Morgensztern, Neal Ready, Melissa L Johnson, et al.
Biorxiv : the Preprint Server for Biology
|
December 25, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma
Mona Foth, Wontak Kim, Kayla T O'Toole, et al.
Cancer Cell
|
April 24, 2026
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma
Rodrigo Entrialgo-Cadierno, Konstantina Morali, Iker Feliu, et al.
Cancer Research
|
May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma
Mona Foth, Wontak Kim, Kayla O'Toole, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal for Immunotherapy of Cancer
|
April 10, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
Steven T Chen, Yevgeniy R Semenov, Allireza Alloo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 5, 2021
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021
David S Ettinger, Douglas E Wood, Dara L Aisner, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
ESMO Open
|
October 24, 2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
Aparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, et al.
Cell
|
May 7, 2026
Disrupted molecular glue complex drives RAS inhibitor resistance
Ben Sang, Ling Feng Ye, Zheng Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Aparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer
Daniel Morgensztern, Neal Ready, Melissa L Johnson, et al.
Biorxiv : the Preprint Server for Biology
|
December 25, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma
Mona Foth, Wontak Kim, Kayla T O'Toole, et al.
Cancer Cell
|
April 24, 2026
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma
Rodrigo Entrialgo-Cadierno, Konstantina Morali, Iker Feliu, et al.
Cancer Research
|
May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma
Mona Foth, Wontak Kim, Kayla O'Toole, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal for Immunotherapy of Cancer
|
April 10, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
Steven T Chen, Yevgeniy R Semenov, Allireza Alloo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 5, 2021
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021
David S Ettinger, Douglas E Wood, Dara L Aisner, et al.
Page
of 7